Ansun BioPharma, Inc., a San Diego, CA-based biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections, completed an $85m Series A financing round.
The round was led by Sinopharm Healthcare Fund and Lilly Asia Ventures, with participation from new investors Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment.
The company intends to use the funds to advance a Phase 3 clinical trial of its experimental anti-viral medication, DAS181.
Led by Dr. Nancy Chang, the interim CEO, Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of DAS181, a potentially first-in-class therapeutic that can be used to treat respiratory viral infections, including, but not limited to influenza, parainfluenza, and metapneumovirus.
The company is currently working with FDA to plan and implement a Phase 3 clinical trial of DAS181 for the treatment of PIV infection in hospitalized and immunocompromised patients. In addition to Breakthrough Designation, DAS181 has also received Fast Track designation by the U.S. FDA for this indication.